Research Article

F806 Suppresses the Invasion and Metastasis of Esophageal Squamous Cell Carcinoma via Downregulating F-Actin Assembly-Related Rho Family Proteins

Lei Xie,1,2 Li-Yan Li,1,2 Duo Zheng,3 Yang-Min Xie,4 Xiu-E Xu,1,5 Li-Hua Tao,5 Lian-Di Liao,1,5 Ying-Hua Xie,1,2 Yin-Wei Cheng,1,2 Li-Yan Xu,1,5 and En-Min Li1,2

1The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong 515041, China
2Department of Biochemistry and Molecular Biology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong 515041, China
3Shenzhen Key Laboratory of Translational Medicine of Tumor, Department of Cell Biology and Genetics, Shenzhen University Health Sciences Center, No. 3688, Nanhai Road, Shenzhen, Guangdong 518080, China
4Experimental Animal Center, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong 515041, China
5Institute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong 515041, China

Correspondence should be addressed to Li-Yan Xu; lyxu@stu.edu.cn and En-Min Li; nmli@stu.edu.cn

Received 11 May 2018; Revised 2 July 2018; Accepted 25 July 2018; Published 19 September 2018

Academic Editor: Ji-Fu Wei

Copyright © 2018 Lei Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Invasion and metastasis are critical pathological and mortal processes in esophageal squamous cell carcinoma (ESCC). Novel drugs, targeting the two cancer migration stages, will augment the treatment options for ESCC therapy and improve overall survival. A novel natural macrolide F806 specifically promotes apoptosis of various ESCC cells. However, whether F806 can inhibit metastasis of ESCC cells needs further evaluation. Here, our data showed that F806 inhibits dynamic F-actin assembly and then suppresses the migration of ESCC cells in vitro and their invasion and metastasis in vivo. The correlation between cancer migration and actin cytoskeleton assembly was consistent with the ability of F806 to prevent the aggregation of Paxillin, an essential protein for focal adhesion formation through binding to the ends of actin filaments. Furthermore, F806 downregulated the expression and activity of the Rho family proteins cell division cycle 42 (CDC42), RAC family small GTPase 1 (RAC1), and RAS homolog family member A (RHOA). Taken together, these results suggest that F806 can suppress cancer invasion and metastasis via interrupting the assembly of migration components involving F-actin.

1. Introduction

Esophageal cancer (EC) has the characteristics of rapid progression, poor prognosis, and poor survival, which make it the eighth most common and sixth most fatal cancer worldwide [1, 2]. The esophageal squamous cell carcinoma (ESCC) is one of two major histological subtypes of EC and accounts for more than 90% of EC cases [3–5]. ESCC is usually diagnosed at advanced stages and the 5-year overall survival rate of the patients with metastatic disease is less than 10% [6, 7], which partly results from the insufficient drugs that target ESCC metastasis. Therefore, it is vital to identify drugs capable of targeting metastatic ESCC and to study their mechanism in ESCC therapy.

Cancer metastasis, composed of a series of multistep and multistage processes, is the principal cause of fatality for patients with drug-resistant tumor cells and is responsible for most cancer deaths [8]. ESCC metastasis requires cells to access invasive and migratory processes, which are initiated by the dynamic assembly of actin cytoskeleton into filopodia and microspike structures [9]. The actin cytoskeleton regulatory proteins, such as Fascin and Ezrin, play crucial roles in the promotion of ESCC cell metastasis through increasing filopodia formation [10, 11]. It can be said that the
dynamic regulation of actin cytoskeleton and the action of its regulatory proteins are still worthy of study, especially in the context of target drug treatment for metastatic ESCC patients.

Our previous research suggested that the novel macrolide analog F806 has higher selectivity and sensitivity for the apoptosis of ESCC cells than that of normal cells ([12] and Supplementary Figure S1), making it a possible candidate target drug. However, it is not clear whether F806 has pharmacological functions to inhibit the invasion and metastasis of ESCC cells. F806 can downregulate expression of integrin beta 1 (ITGB1) and growth factor receptor bound protein 2 (GRB2), resulting in ESCC cell apoptosis [12, 13]. The studies showed that ITGB1- and GRB2-associated signaling pathways not only take part in proliferation regulation and the induction of different signaling cascades but also extensively participate in the promotion of cancer cell migration-related processes [14]. Integrins coupled to the actin cytoskeleton via the cytoskeleton-binding proteins including GRB2 and Paxillin then develop into the focal complex to form a focal adhesion [15–17], which adhere to or slowly glide along the substrate as the cell moves via the dynamic assembly [18, 19]. Therefore, we hypothesized that F806 may have a new function of disrupting the actin cytoskeleton assembly and focal adhesion, leading to inhibition of cancer cell metastasis. To prove this hypothesis, we firstly characterize the pharmacological function of F806 in inhibiting ESCC migration and metastasis in vitro and in vivo and then display an antimetastasis mechanism of F806 in this study.

2. Material and Methods

2.1. Chemicals and Cell Lines. F806 (purity ≥ 98.5%) was discovered and provided by Fujian Institute of Microbiology, China [12, 13]. Cell lines used in this study were previously described [20]. EC109 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) and KYSE510 cells were maintained in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (GIBCO). KYSE510 cells were transiently transfected with actin expression gene vectors (LifeAct-RFP) for 24 hrs. The cells were grown on coverslips in 24-well plate were treated with F806 (20 μM) for 24 hrs. Then, cells were fixed with 4% paraformaldehyde for 20 minutes and permeabilized with 0.1% Triton X-100 in PBS and stained with a solution containing 5 μg/mL phalloidin-FITC at 4°C overnight in the dark. After washing, the samples were immediately analyzed by flow cytometry using a Coulter Epics XL flow cytometer (Beckman-Coulter Inc, Brea, CA, USA).

2.2. Cell Migration Assay. The effect of F806 treatment on the migration of ESCC cells was evaluated using a modified Boyden chamber migration assay [11]. Briefly, ESCC cells (5×10⁴ cells/well) were cultured in serum-free RPMI 1640 medium with F806 (a final concentration of 20 μM) in the top chambers of 24-well transwell plates (Corning Costar, Cambridge, MA). And the lower chambers were filled with RPMI 1640 medium with 10% FBS. After 24 hrs, cells migrating to the underside of the top chamber were stained with crystal violet in 2% ethanol and quantified by counting 10 random fields under a light microscope (200×). Data obtained from 3 separate chambers are shown as mean values.

2.3. Regional Lymph Node Metastasis in Nude Mice. The experimental metastasis in nude mice was performed as described previously [21]. Five-week-old male nude mice were purchased from Vital River Laboratories (Beijing, China). All animal studies were conducted in accordance with protocols approved by the Animal Research Committee of the Shantou Administration Center and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Twenty-one mice were equally divided into three groups at random. A suspension of 1.0×10⁶ KYSE510 cells in 100 μl serum-free 1640 medium was inoculated subcutaneously into the left hind footpad of each mouse on Day 0. The growth of footpad tumors was monitored daily, and tumor size was measured every three days, and inguinal lymph nodes were palpated at the same time. On Day 7 after tumor cell injection, the footpad tumors were palpable and the average size was around 25 mm³, and drug administration was initiated. Briefly, a 100 mg/ml F806 stock solution prepared in 100% ethyl alcohol was diluted in 0.9% NaCl containing 5% Tween-80 and 5% polyethylene glycol-400 (Sigma, St Louis MO, USA) to give a dose of 4 mg/kg or 8 mg/kg, in 200 μL solutions, which was intraperitoneally administered daily for 21 days. Mice were euthanized on Day 28 and inguinal lymph nodes were excised and preserved in formalin for histological analysis by hematoxylin-eosin (HE).

2.4. Flow Cytometry Analysis. Cells treated with F806 for 24 hrs were harvested and fixed with 70% cold ethanol in phosphate-buffered saline (PBS) at 4°C overnight. Subsequently, the samples were permeabilized with 0.1% Triton X-100 in PBS and stained with a solution containing 5 μg/mL phalloidin-FITC at 4°C overnight in the dark. After washing, the samples were immediately analyzed by flow cytometry using a Coulter Epics XL flow cytometer (Beckman-Coulter Inc, Brea, CA, USA).

2.5. Immunofluorescence and Live Imaging. Immunofluorescence staining was performed as previously described [10]. Briefly, cells grown on coverslips in 24-well plate were treated with F806 (20 μM) for 24 hrs. Then, cells were fixed with 4% paraformaldehyde for 20 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes. Cells stained with phalloidin-FITC (5 μg/mL) were analyzed using an Olympus FV1000 confocal microscope (Olympus, Tokyo, Japan).

Live imaging was performed as previously described [11]. Briefly, KYSE510 cells were transiently transfected with actin expression gene vectors (LifeAct-RFP) for 24 hrs. The cells were plated on imaging chamber with 10 μg/mL fibronectin-coated for 24 hrs and then were supplemented with a final concentration of 20 μM F806 and incubated at 37°C on a heated stage 30 minutes later, live-cell imaging began, and the behavior of actin in cell filopodia was visualized for 2 hrs using a confocal microscope (LSM880, Carl Zeiss MicroImaging, Inc.) with a 40×, 1.43 NA lens.

2.6. Analysis of G/F-Actin Ratio. The ratio of G-actin to F-actin was determined using the G/F-actin in vivo assay kit (Cytoskeleton, Inc., Denver, CO, USA) according to the manufacturer’s instructions. Briefly, after the treatment with or without F806 (20 μM) for 24 hrs, cells were homogenized in lysis buffer and F-actin stabilization buffers, followed by centrifugation for 1 hr at 100,000 ×g at 37°C to pellet F-actin.
The supernatants containing G-actin were collected, and the pellets containing F-actin were resuspended in F-actin depolymerizing solution. Western blots were performed as described previously [22]. Appropriate antiactin (sc-47778) and HRP-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA, 1:5000).

2.7. Rho GTPase Activation and Expression Assay. After the treatment with F806 (20 μM) for 24 hrs, cells were homogenized. Pull-down of the guanosine triphosphate (GTP)-bound form of Rho family GTPases was performed using RHOA and CDC42/RAC1 activation assay kits (Cytoskeleton) in accordance with the manufacturer’s instructions. For Rho GTPase expression assay, the ESCC cells were transfected by flag-RAC1 and flag-RHOA plasmid, after 24 hrs, pretreated with MG132 (20 μM) for 1 hr, and then jointly treated with F806 (20 μM) for another 24 hrs. Total cell lysates were lysed on ice in RIPA buffer containing 1× complete protease inhibitor cocktail (Roche) and sonicated. Western blots were performed as described previously [22].

2.8. Statistical Analyses. Data analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). A two-way ANOVA or Student’s t test was used to determine the significance of differences between groups, and a P < 0.05 was deemed statistically significant. Data were plotted as mean ± SD or mean ± SEM, of at least three independent experiments, using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).

3. Results

3.1. F806 Suppresses the Migration of EC109 and KYSE510 Cells In Vitro and Their Invasion and Metastasis In Vivo. The potential of F806 to inhibit the migration of EC109 and KYSE510 cells was initially examined in a transwell cell migration assay. F806 (20 μM) reduced the number of cell colonies on the bottom surface of the chamber (Figure 1(a)). Cell migration was reduced by about 52% and 66% in F806-treated EC109 and KYSE510 cells, respectively (Figure 1(b)). The results indicated that the migration of ESCC cells in vitro was clearly suppressed by F806.

KYSE510 cells were injected into the footpads of mice, then F806 treatment began on Day 7, and tumor size was measured on Day 28 (Figures 2(a) and 2(b)). Tumor size was reduced by about 53% or 31% following administration of 4 mg/kg or 8 mg/kg F806, respectively (Figure 2(c)). The data from the corresponding groups showed that the ratio of lymph node metastasis was reduced by about 34% or 46% (Figure 2(d)). Similarly, HE stain suggested that the infiltrating cancer cells were distinctly reduced by F806 in the inguinal lymph node area of mice (Figure 2(e)). Therefore, the conclusion is that F806 can markedly inhibit the migration of ESCC cells in vitro and their invasion and metastasis in vivo.

3.2. Regulation of F806 on Actin Cytoskeleton Rearrangement. Previous reports showed that F806 can downregulate expression of ITGB1 and GRB2 proteins that participate in the connection of actin fibers to plasma membrane, in ESCC cell lines [12,13]. Therefore, we examined whether the inhibitory effect of F806 on ESCC invasion and metastasis was correlated with alterations in F-actin rearrangement. To do this, we used flow cytometry to measure the effects of F806 on the transformation of G-actin to F-actin. We found that fluorescence intensity was dramatically altered by F806 in accordance with the distinction of fluorescence intensity between G-actin and F-actin (Figure 3(a)). At the cell level, actin assembly was inhibited by F806, resulting in a significant reduction in the number and length of stress fibers and filopodia after the treatment with F806 (20 μM).
Figure 2: F806 suppresses the invasion and metastasis of ESCC cells in vivo. (a) The regional lymph node metastasis models of ESCC xenograft. (b) The growth curves of tumor volume were plotted in control and treated groups of xenograft models. (c) The volume percentage of tumors from the xenograft models in control and F806-treated mice. (d) Representative hematoxylin-eosin staining of lymph node metastasis sections from the inguinal regions. (e) The lymph node metastasis ratio from the inguinal regions. Scale bar = 50 μm. Data are mean ± SD, * P < 0.05; ** P<0.01; *** P<0.001, compared to the control group; n=7. F-4: 4 mg/kg F806; F-8: 8 mg/kg F806.
Figure 3: F806 induces rearrangement of the F-actin cytoskeleton of ECCC cells. (a) The fluorescence value of F-actin (grey peak) and G-actin (white peak) was measured by flow cytometry in F806-treated or control EC109 cells. Data are mean ± SD and ** P<0.01, compared to the control group; n = 6. (b) EC109 and KYSE510 cells stained with phalloidin were analyzed using an Olympus FV1000 confocal microscope. Scale bar = 10 μm. (c) Exogenous RFP-actin-forming filopodia in KYSE510 cells were visualized and recorded by a confocal microscope with a 40×, 1.43 NA lens, Plan-Apochromat objective. (d) The G-actin/F-actin ratio was determined by a G/F-actin in vivo assay kit. C: control; F: F806; T: total protein; S: supernatant; P: pellet.
for 24 hrs (Figure 3(b)) and after the treatment with F806 (20 μM) for 30 minutes, when the behavior of actin assembly was visualized for following 2 hrs using the live imaging system in a confocal microscope (Figure 3(c) and Supplementary video). At the molecular level, the data indicated that F806 reduced the level of F-actin, suggesting that formation of actin filaments, from G-actin, was suppressed by F806 (Figure 3(d)).

3.3. Effects of F806 on Expression and Activity of the Rho Family Proteins. Rho family proteins, CDC42, RHOA, and RAC1, are involved in the upstream regulation of actin filament formation [23], so we tested the effect of F806 on CDC42, RHOA, and RAC1 protein expression. We found that their expression was reduced by F806 treatment in both EC109 and KYSE510 cells (Figures 4(a) and 4(b)). Importantly, the activity form of CDC42 (CDC42-GTP) also decreased in the F806 treatment group compared to the control group. In order to investigate the reasons of downregulation of Rho family proteins, we pretreated the cells with MG132, a proteasome inhibitor, and then added F806. Western blots showed that F806 lost the ability to reduce Rho family proteins after treatment with MG132, suggesting that F806 inhibited the activity of Rho family proteins.

Figure 4: The inhibition of F806 on expression and activity of CDC42, RHOA, and RAC1. (a) Activity and expression analysis of CDC42 were detected by a Rho GTPase activation assay kit. (b) The expression of RHOA and RAC1 was detected by Western blot. (c) Western blots analysis of flag-RHOA and flag-RAC1 expression in ESCC cells after pretreatment with MG132 and then added F806. (d) The colocalization of actin filament and focal adhesion marker Paxillin was analyzed by immunofluorescent staining in EC109 and KYSE510 cells. Scale bar = 10 μm.
by regulating proteasome activity. Furthermore, since Rho family proteins regulate the attachment of actin cytoskeleton to focal adhesion [24] and Paxillin is one of the key focal adhesion-associated proteins [25], we evaluated the actin assembly by detecting the location of Paxillin. The results suggested that F806 interfered with Paxillin aggregation at the ends of actin filaments (Figure 4(d)). Thus, we conclude that F806 suppresses the assembly of actin filaments and their linkage to Paxillin via inhibiting the expression of Rho family.

4. Discussion

Due to the difficulty in identifying lead compounds with pharmacological study of ESCC has been relatively ignored, the target drugs for ESCC are scarce. Therefore, it is of crucial importance for metastatic ESCC therapy to find novel target compounds selectively suppressing ESCC tumorigenicity. We previously showed that F806 displays greater specificity and stronger lethality toward ESCC cells [12], but not for normal immortalized epithelia cells (Supplementary Figure 1). Therefore, we extended our study of F806 to explore its suppressive mechanisms for various ESCC processes.

Our previous studies showed that F806 suppresses cancer progression; though it downregulates the protein expression of actin cytoskeleton linkers ITGB1 and GRB2 [12, 13], proteins are involved in the formation of focal adhesions, which implies F806 can control dynamic changes of the cytoskeleton. We determined whether F806 could take part in the regulation of actin assembly and cancer metastasis by analyzing the function of F806-downregulating proteins in the above two biological processes [24, 26–28]. Nevertheless, we have previously paid close attention to the therapeutic efficacy of F806 for ESCC survival and growth [12, 13, 29, 30], but its regulation for ESCC migration processes had yet to be explored. Our results firstly suggest that F806, as a potential candidate compound, suppresses ESCC migration in vitro and in vivo (Figures 1 and 2). Thus, the current study advances ESCC target drug development.

Because F806 may have pleiotropic effects on inhibiting ESCC development, it needs to be further confirmed that the inhibitory effect of F806 on ESCC migration independent of its suppression on ESCC growth. The results showed that the dose-response of F806-mediated inhibition of metastasis was not completely identical with inhibition of tumor size (Figures 2(c) and 2(e)), which suggested that F806-mediated suppression of ESCC metastasis did not completely rely on F806 against ESCC proliferation. Migratory protrusions of cellular movement, termed filopodia, lamellipodia, and invadopodia, are initiated by actin polymerization underlying the inner side of cytoplasmic membrane [31]. Based on the correlation of the above mentioned ESCC metastasis-related processes mediated by F806, F806 inhibition of actin assembly was supported by our demonstration that F806 disturbs actin assembly (Figure 3).

Although we understand that F806 suppresses ESCC migration and disturbs the dynamic actin assembly, we needed to determine the proteins regulating above two physiological processes. CDC42, RAC1, and RHOA are well characterized for actin reorganization, cancer invasion, and metastasis in various cancers [24, 32–35] but are still incompletely characterized in ESCC [36–41]. Examination of the effects of F806 on their expression showed that F806 inhibits their activity via reducing their expression (Figures 4(a) and 4(b)).

CDC42, RAC1, and RHOA are not only involved in actin assembly and cell migration [42, 43] but also participate in connecting Paxillin with actin filaments and focal adhesions [44]. Paxillin has emerged as a crucial coordinator of Rho GTPase activity in the context of cell migration [45]. We evaluated the activity regulated by F806 via determining the colocalization of Paxillin and actin filaments. When ESCC cells were exposed to F806, the aggregation of Paxillin was blocked at the ends of actin filaments close to the interior surface of plasma membranes; the depolymerization of actin filaments was promoted (Figure 4(c)). In addition, we previously showed that ITGB1, a constituent of the focal adhesion complex, is also reduced by F806 [12]. The loss of ITGB1 may result in the separation of Paxillin from the intracellular surface of cell adhesion sites. Because Paxillin plays an important role in the recruitment of an array of GTPase activators to sites of cell adhesion, loss of Paxillin at these sites may in turn further inhibit CDC42, RAC1, and RHOA activity. Therefore, we examined CDC42, RAC1, and RHOA as potential target proteins of F806 based on their role in the formation and turnover of actin filaments, as well as cancer invasion and metastasis.

F806 may also regulate other upstream signal complexes involved in cytoskeletal organization, cancer apoptosis, and autophagy. In the future, we will utilize F806 as a potent tool to find vital proteins, further elaborating their mechanism in ESCC development, to ultimately develop the clinical drugs for ESCC therapy.

5. Conclusion

In conclusion, our results demonstrated that the therapeutic effects of F806 on invasion and metastasis of ESCC via inhibiting the function of Rho family proteins for regulating F-actin assembly and the combination of Paxillin with F-actin ends. Therefore, it can be said that we found the novel efficacy of F806 interrupting Rho family proteins/F-actin assembly/ESCC migration pathway in metastatic ESCC.

Abbreviations

ESCC: Esophageal squamous cell carcinoma
EC: Esophageal cancer
CDC42: Cell division cycle 42
RAC1: Rac family small GTPase 1
RHOA: Ras homolog family member A
ITGB1: Integrin beta 1
GRB2: Growth factor receptor bound protein 2.

Data Availability

No data were used to support this study.
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors’ Contributions

Lei Xie and Li-Yan Li contributed equally to this work.

Acknowledgments

The authors thank Professor Stanley Li Lin from the Department of Cell Biology of Shantou University Medical College for the assistance in revising the manuscript. This work was supported by the National Natural Science Foundation of China [Grant no. 81602630], the National Cohort of Esophageal Cancer of China [Grant no. 2016YFC0901400], the Educational Commission of Guangdong Province [Grant no. 2017KQNCX070], the Special Fund for Science and Technology Innovation Strategy of Guangdong Province [Grant no. 2018A03030220], and the Department of Education, Guangdong Government, under the Top-Tier University Development Scheme for Research and Control of Infectious Diseases.

Supplementary Materials

Supplementary Figure S1: MTS assay. Supplementary Method: The noncancer cells were cultured for 24 hrs in 96-well plates and then were treated with 0, 20, and 40 μM F806 for 24 hours. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium inner salt (MTS) assay was performed according to the manufacturer’s instructions (Promega). MTS was bioreduced by the cells into a colored formazan product that reduces absorbance at 492 nm. Raw data were normalized against those of medium blank control. Data in each group obtained from 3 separate wells were shown as mean values; mean ± SD; n=3. Supplementary Video: Immunofluorescence live imaging. The video shows the effect of F807 on exogenous RFP-actin-forming filopodia in KYSE510 cells (control is the SD; n=3.

References

[1] Y. Zhang, “Epidemiology of esophageal cancer,” World Journal of Gastroenterology, vol. 19, no. 34, pp. 5598–5606, 2013.
[2] K. J. Napier, M. Scheerer, and S. Misra, “Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities,” World Journal of Gastrointestinal Oncology, vol. 6, no. 5, pp. 112–120, 2014.
[3] B. Panda, A. Rout, S. Pati et al., “Tobacco control law enforcement and compliance in odisha, india-implications for tobacco control policy and practice,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 9, pp. 4631–4637, 2012.
[4] C. Gholipour, R. A. Shalchi, and M. Abbasi, “A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003,” Diseases of the Esophagus, vol. 21, no. 4, pp. 322–327, 2008.
[5] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.
[6] R. Ishihara, H. Tanaka, H. Ishi et al., “Long-term outcome of esophageal mucosal squamous cell carcinoma without lymphovascular involvement after endoscopic resection,” Cancer, vol. 112, no. 10, pp. 2166–2172, 2008.
[7] G. D. Stoner and A. Gupta, “Etiology and chemoprevention of esophageal squamous cell carcinoma,” Carcinogenesis, vol. 22, no. 11, pp. 1737–1746, 2001.
[8] C. M. Fife, J. A. McCarroll, and M. Kavallaris, “Movers and shakers: Cell cytoskeleton in cancer metastasis,” British Journal of Pharmacology, vol. 171, no. 24, pp. 5507–5523, 2014.
[9] M. Yilmaz and G. Christofori, “EMT, the cytoskeleton, and cancer cell invasion,” Cancer and Metastasis Reviews, vol. 28, no. 1-2, pp. 15–33, 2009.
[10] F.-M. Zeng, X.-N. Wang, H.-S. Shi et al., “Fascin phosphorylation sites combine to regulate esophageal squamous cancer cell behavior,” Amino Acids, vol. 49, no. 5, pp. 943–955, 2017.
[11] L.-Y. Li, Y.-H. Xie, Y.-M. Xie et al., “Ezrin Ser66 phosphorylation regulates invasion and metastasis of esophageal squamous cell carcinoma cells by mediating filopodia formation,” The International Journal of Biochemistry & Cell Biology, vol. 88, pp. 162–171, 2017.
[12] L. Li, H. Jiang, Y. Xie et al., “Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking integrin activation,” Oncotarget, vol. 6, no. 18, 2015.
[13] L.-Y. Li, K. Zhang, H. Jiang et al., “Quantitative proteomics reveals the downregulation of GRB2 as a prominent node of F806-targeted cell proliferation network,” Journal of Proteomics, vol. 117, pp. 145–155, 2015.
[14] A. Giubellino, T. R. Burke Jr., and D. P. Bottaro, “Grb2 signaling in cell motility and cancer,” Expert Opinion on Therapeutic Targets, vol. 12, no. 8, pp. 1021–1033, 2008.
[15] K. Burridge and M. Chrzansowska-Wodnicka, “Focal adhesions, contractility, and signaling,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 463–519, 1996.
[16] R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002.
[17] E. Zamir, M. Katz, Y. Posen et al., “Dynamics and segregation of cell-matrix adhesions in cultured fibroblasts,” Nature Cell Biology, vol. 2, no. 4, pp. 191–196, 2000.
[18] C. M. Regen and A. F. Horwitz, “Dynamics of β1 integrin-mediated adhesive contacts in motile fibroblasts,” The Journal of Cell Biology, vol. 119, no. 5, pp. 1347–1359, 1992.
[19] L. B. Smilnenov, A. Mikhailov, R. J. Pelham Jr., E. E. Marcantonio, and G. G. Gundersen, “Focal adhesion motility revealed in stationary fibroblasts,” Science, vol. 286, no. 5442, pp. 1172–1174, 1999.
[20] G. Q. Lv, H. Y. Zou, and L. D. Liao, “Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 αe3, in esophageal squamous cell carcinoma,” The International Journal of Biochemistry & Cell Biology, vol. 92, no. 5, pp. 379–389, 2014.
[21] W.-K. Fang, L.-D. Liao, L.-Y. Li et al., “Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signaling in esophageal squamous cell carcinoma,” The Journal of Pathology, vol. 231, no. 2, pp. 257–270, 2013.
[22] J. Xie, L. Xu, J. Wu et al., “Involvement of CYR61 and CTGF in the Fascin-Mediated Proliferation and Invasiveness of Esophageal Squamous Cell Carcinomas Cells,” The American Journal of Pathology, vol. 176, no. 2, pp. 939–951, 2010.

[23] P. Aspenström, Å. Fransson, and J. Saras, “Rho GTpases have diverse effects on the organization of the actin filament system,” Biochemical Journal, vol. 377, no. 2, pp. 327–337, 2004.

[24] C. D. Nobes and A. Hall, “Rho, Rac, and Cdc42 GTpases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia,” Cell, vol. 81, no. 1, pp. 53–62, 1995.

[25] C. E. Turner, “Paxillin and focal adhesion signalling,” Nature Cell Biology, vol. 2, no. 12, pp. E231–E236, 2000.

[26] N. Tapon and A. Hall, “Rho, Rac and Cdc42 GTpases regulate the organization of the actin cytoskeleton,” Current Opinion in Cell Biology, vol. 9, no. 1, pp. 86–92, 1997.

[27] J. Chen, Y. Yao, C. Gong et al., “CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3,” Cancer Cell, vol. 19, no. 4, pp. 541–555, 2011.

[28] P. J. Keely, J. K. Westwick, I. P. Whitehead, C. J. Der, and L. V. Parise, “Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K,” Nature, vol. 390, no. 6660, pp. 632–636, 1997.

[29] W. Huang, M. Ye, L.-R. Zhang et al., “FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation,” Molecular Cancer, vol. 13, article 150, 2014.

[30] W. Huang, Q.-D. Wu, M. Zhang et al., “Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib,” Cancer Letters, vol. 356, no. 2, part B, pp. 862–871, 2015.

[31] H. Yamaguchi and J. Condeelis, “Regulation of the actin cytoskeleton in cancer cell migration and invasion,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1773, no. 5, pp. 642–652, 2007.

[32] L. van Aelst and C. D’Souza-Schorey, “Rho GTpases and signaling networks,” Genes & Development, vol. 11, no. 18, pp. 2295–2322, 1997.

[33] A. Hall, “Rho GTpases and the actin cytoskeleton,” Science, vol. 279, no. 5350, pp. 509–514, 1998.

[34] R. Rathinam, A. Berrier, and S. K. Alahari, “Role of Rho GTpases and their regulators in cancer progression,” Frontiers in Bioscience, vol. 16, no. 7, pp. 2561–2571, 2011.

[35] E. Sahai and C. J. Marshall, “RHO - GTpases and cancer,” Nature Reviews Cancer, vol. 2, no. 2, pp. 133–142, 2002.

[36] Q. Yang, G.-Y. Luo, Y. Li, H.-B. Shan, H.-Y. Wang, and G.-L. Xu, “Expression of Rac-1 related to tumor depth, lymph node metastasis and patient prognosis in esophageal squamous cell carcinoma,” Medical Oncology, vol. 30, no. 4, article 689, 2013.

[37] T. Muramatsu, K.-I. Kozaki, S. Imoto et al., “The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma,” Oncogene, vol. 35, no. 40, pp. 5304–5316, 2016.

[38] R.-C. Tseng, J.-M. Chang, J.-H. Chen et al., “Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal cancer metastasis and poor prognosis,” Journal of Thoracic Oncology, vol. 10, no. 1, pp. 189–198, 2015.

[39] A. Faried, M. Nakajima, M. Sohda, T. Miyazaki, H. Kato, and H. Kuwano, “Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma,” European Journal of Surgical Oncology, vol. 31, no. 4, pp. 410–414, 2005.